Effect of dibutyltin(IV) on the ultrastructure of African Trypanosoma spp

M N Shuaibu1, H Kanbara, T Yanagi

  • 1Protozoology Department, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, 852-8523 Nagasaki-shi, Japan. nshuaibu@yahoo.com

Parasitology Research
|November 8, 2003
PubMed

Insights

Dibutyltins cause severe damage to African trypanosomes, including kinetoplast and DNA fragmentation. This organometallic compound shows potential for treating African trypanosomiasis.

Area of Science:

  • Parasitology
  • Toxicology
  • Medicinal Chemistry

Background:

  • Diorganotins (R2SnX2) exhibit diverse biological activities.
  • African trypanosomiasis remains a significant health concern, necessitating novel therapeutic strategies.
  • Understanding the mechanisms of anti-parasitic compounds is crucial for drug development.

Purpose of the Study:

  • To investigate the ultrastructural effects of dibutyltins (Bu2SnX2) on in vitro cultured African Trypanosoma spp.
  • To characterize the toxic mechanisms and potential of diorganotins in trypanosome cell death.

Main Methods:

  • Transmission and scanning electron microscopy to observe morphological changes in parasites.
  • Fluorescence microscopy using 4,6-diamidine-2-phenylindole stain to assess kinetoplast DNA (kDNA) integrity.
  • Agarose gel electrophoresis to analyze kDNA fragmentation patterns.

Main Results:

  • Dibutyltins induced significant ultrastructural damage, including kinetoplast perturbation, cytoplasmic swelling, and membrane disintegration.
  • kDNA fragmentation was observed in parasites exposed to dibutyltins, correlating with cell death.
  • No direct fragmentation of isolated kDNA by dibutyltins in vitro was detected, suggesting an indirect mechanism.

Conclusions:

  • Dibutyltins induce severe, irreparable damage to African trypanosomes, involving kDNA fragmentation.
  • The findings suggest a potential therapeutic role for organometallic compounds, specifically dibutyltins, in treating African trypanosomiasis.
  • Further research into organometallic compounds could lead to novel anti-trypanosomal drugs.

Related Concept Videos

American Trypanosomiasis01:22

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...